# Moleculin Biotech (MBRX) — News

MBRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/mbrx/news

## Recent headlines

- [Molecularin Biotech completes enrollment in part A of phase 2/3 r/r AML miracle trial, keeping program on track for Q1 2027 data readout](https://www.ainvest.com/news/molecularin-biotech-completes-enrollment-part-phase-2-3-aml-miracle-trial-keeping-program-track-q1-2027-data-readout-2609) — AInvest Wire, Sep 29, 2026
  Moleculin Biotech, Inc. (Nasdaq: MBRX) has completed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial (MB-108) for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) with its investigational drug Annamycin. The trial, which evaluates Annamycin in combination with…
- [Molecularin Biotech secures Mexican patent protecting lung-targeted liposomal annamycin through 2040](https://www.ainvest.com/news/molecularin-biotech-secures-mexican-patent-protecting-lung-targeted-liposomal-annamycin-2040-2609) — AInvest Wire, Sep 23, 2026
  Moleculin Biotech, Inc. (Nasdaq: MBRX) has secured a patent in Mexico for its lung-targeted liposomal Annamycin formulation, extending its intellectual property (IP) protection through 2040. This development adds to the company’s growing global IP portfolio for Annamycin, a novel anthracycline drug…
- [Moleculin Biotech, Inc.: H.C. Wainwright cuts target price to $3 from $22](https://www.ainvest.com/news/moleculin-biotech-wainwright-cuts-target-price-3-22-2608) — AInvest Wire, Aug 28, 2026
  H.C. Wainwright has revised its price target for Moleculin Biotech, Inc. (MBRX.US), reducing it from $22 to $3, reflecting a significant downward adjustment in its valuation outlook for the biotechnology firm. The move signals a shift in the firm’s assessment of Moleculin’s near-term prospects,…
- [Molculin announces pricing of $9.3 million public offering](https://www.ainvest.com/news/molculin-announces-pricing-9-3-million-public-offering-2607) — AInvest Wire, Jul 31, 2026
  Moleculin Biotech, Inc. (Nasdaq: MBRX) announced the pricing of a public offering to raise approximately $9.3 million in gross proceeds, according to a registration statement filed with the U.S. Securities and Exchange Commission (SEC). The offering includes the sale of up to 4.6 million common…
- [Molculin Biotech - Miracle Trial Part A final treatment expected September 2026; unblinded results December 2026–February 2027](https://www.ainvest.com/news/molculin-biotech-miracle-trial-part-final-treatment-expected-september-2026-unblinded-results-december-2026-february-2027-2607) — AInvest Wire, Jul 31, 2026
  Moleculin Biotech, Inc. (Nasdaq: MBRX) continues to advance its pivotal Phase 2B/3 MIRACLE trial of Annamycin in combination with cytarabine for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML). The trial, which is designed to evaluate the efficacy and safety of Annamycin in…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).